# Jill Carroll

> Jill Carroll is a Series A investor at SR One backing Biotechnology and Health Care. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [SR One](https://shizune.co/investors/profile/sr-one)
- Total investments: 10
- Last investment: Jan 2026
- Lead investor: 70%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/jill-carroll-1777681a

Jill Carroll is a Series A investor at SR One focused on Biotechnology and Health Care. Jill joined SR One in 2011 with a background in biotech partnering and commercial development. Prior to SR One, Jill was responsible for Corporate Development at Dynavax Technologies, where she was involved in multiple pharma partnering deals as well as substanial private and public financings. Previously, Jill was a consultantspecializing in health care at Clearview Projects and Mercer Management Consulting.Jill received her BS in Chemistry from Duke University, and her MS in Biochemistry, Cellular and Molecular Biology from Johns Hopkins University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 60% |
| Health Care | 5 | 50% |
| Therapeutics | 4 | 40% |
| Medical | 3 | 30% |
| Biopharma | 2 | 20% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 40% |
| Series B | 3 | 30% |
| Series C | 2 | 20% |
| Series D | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AirNexis Therapeutics | AirNexis Therapeutics develops clinical-stage therapies for chronic obstructive pulmonary disease and other pulmonary conditions. | $200M | Series A | Jan 09, 2026 |  |
| Poplar Therapeutics | Poplar Therapeutics anti-IgE therapy treats atopic diseases such as food allergy, allergic asthma, and atopic dermatitis. | $50M | Series A | Jan 07, 2026 |  |
| Avalyn Pharma | Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novelinhaled therapeutics.Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington. | $100M | Series D | Jul 22, 2025 |  |
| Avalyn Pharma | Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novelinhaled therapeutics.Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington. | $175M | Series C | Sep 27, 2023 |  |
| Odyssey Therapeutics | Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines. | $168M | Series B | Oct 13, 2022 |  |
| Odyssey Therapeutics | Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines. | $218M | Series A | Dec 07, 2021 |  |
| HotSpot Therapeutics | HotSpot Therapeutics is a biotech startup that focuses on the development of allosteric therapies targeting regulatory sites on proteins. It develops a therapy platform to discover medicines and provide proper treatment to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspotstructures, harnessing the power of data science in its multidisciplinary approach to drug discovery, and helps patients to get treatment against several diseases.HotSpot Therapeutics was founded in 2017 and is headquartered in Boston, Massachusetts. | $100M | Series C | Nov 29, 2021 |  |
| HotSpot Therapeutics | HotSpot Therapeutics is a biotech startup that focuses on the development of allosteric therapies targeting regulatory sites on proteins. It develops a therapy platform to discover medicines and provide proper treatment to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspotstructures, harnessing the power of data science in its multidisciplinary approach to drug discovery, and helps patients to get treatment against several diseases.HotSpot Therapeutics was founded in 2017 and is headquartered in Boston, Massachusetts. | $65M | Series B | May 21, 2020 |  |
| Arch Oncology | Formerly Known as Vasculox. Tioma is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. The company's functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses. | $86M | Series A | Aug 16, 2016 |  |
| AGTC | Applied Genetics Technologies Corporation (AGTC) is developing therapies designed to transform the lives of patients with severe diseases, offering hope to patients with unmet medical needs. With a highly specialized team of physicians and researchers, They use cutting-edge techniques to develop treatments for patients that have diseases caused bybroken genes. They use gene therapy, which replaces those broken genes with normal functional genes, allowing a patient’s own body to produce proteins to treat their illness. A single injection provides long-lasting treatment, leading to a better quality of life for patients worldwide. | $37.5M | Series B | Nov 19, 2012 |  |

10 of 10 investments shown.

## Co-investors
- [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management) — VC Fund, 3 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 3 deals together
- [Pivotal bioVenture Partners](https://shizune.co/investors/profile/pivotal-bioventure-partners) — VC Fund, 3 deals together
- [RiverVest](https://shizune.co/investors/profile/rivervest) — VC Fund, 3 deals together
- [T. Rowe Price](https://shizune.co/investors/profile/t-rowe-price) — VC Fund, 3 deals together
- [Vida Ventures](https://shizune.co/investors/profile/vida-ventures) — VC Fund, 3 deals together

## About SR One

VC Fund · Cambridge, United States

SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested approximately 800 million in more than 180 companies.

5 contacts available at SR One.

| Name | Title | Profile |
| --- | --- | --- |
| Jill Carroll | Partner | https://shizune.co/investors/profile/jill-carroll |
| Simeon George | Chief Executive Officer | https://shizune.co/investors/profile/simeon-j-george |
| Christopher Y. Chai | Venture Partner | https://shizune.co/investors/profile/christopher-y-chai |
| Iqbal Mufti | Partner | https://shizune.co/investors/profile/iqbal-mufti-e58a |
| Jens Eckstein | President | https://shizune.co/investors/profile/jens-eckstein |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Jill Carroll invest in?

Jill Carroll invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jill Carroll last invest?

The most recent investment recorded for Jill Carroll closed in Jan 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co